Skip to main content


Health

Novartis says that it now seeks approval for serelaxin. Researchers say that in a study of 1,161 patients, the drug cut deaths from any cause at six months by 37 percent and led to a marked reduction in worsening of heart failure during hospitalization.
467 of 1454




Newsletter Sign Up

Daily Readings

Reading 1, Acts 3:11-26
Everyone came running towards them in great excitement, to the ... Read More

Psalm, Psalms 8:2, 5, 6-7, 8-9
even through the mouths of children, or of babes in arms, you ... Read More

Gospel, Luke 24:35-48
Then they told their story of what had happened on the road and ... Read More

Saint of the Day

April 24 Saint of the Day

St. Fidelis of Sigmaringen
April 24: Franciscan Capuchin martyr. He was born Mark Rey is Sigmaringen, ... Read More